Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

gn up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements
This press release contains "forward-looking" statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development and our ability to submit the above-referenced tosedostat data to the FDA in the coming weeks. Such statements are subject to risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the Company's securities. Specifically, the risks and uncertainties that could affect our ability to address FDA requests or the development of tosedostat more generally include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with tosedostat in particular including, without limitation, the potential failure of tosedostat to prove safe and effective as determined by the FDA and/or the European Medicines Agency; determinations by regulatory, patent, and administrative governmental authorities; competitive factors; technological developments; costs of developing and producing tosedostat; the risk that the FDA may expand its information request or initiate a complete clinical hold or take other actions; and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission, including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. The Company can give no assurances that any results or events projected or contemplated by its forward-looking statements will in fact occur and the Company cautions you not to place undue reliance on these statements. The Company undertakes no duty to update these forward-looking statements to reflect any future events, d
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Drug Administration (FDA) has granted orphan drug status to ... "The FDA Office of Orphan Products Development ... to identify and designate drug candidates that could potentially ... development of such products," said Craig M. Audet ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... -- Cepheid (NASDAQ: CPHD) announced today the release of ... test for rapid, accurate and reliable determination of ... infection. The test will be marketed as a ... In Vitro Diagnostic Medical Devices, bringing the ... XC runs on Cepheid,s GeneXpert ® System, ...
Breaking Medicine Technology:Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 ... weight are at risk later in life of having smaller, ... for heart disease, according to a pair of new studies. ... disadvantages, researchers in both studies -- published online Sept. 1 ... be overcome. Education appeared to negate the potential harmful ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 2014 National law firm, ... has filed an application for attorneys’ fees and ... action litigation brought over Flushmate flushing mechanisms. In ... Counsel in this litigation includes Birka-White Law Offices; ... Partners, LLP; Levin Fishbein, Sedran & Berman, LLP; ...
(Date:9/2/2014)... Lseat.com is one of the most popular suppliers of useful ... items; no professional installation is required. Customers do not need ... over the cars’ seats. That can save plenty of time ... various kinds of practical covers. , In addition, it ... seat covers . Also, the company has launched a special ...
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
Breaking Medicine News(10 mins):Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... from the Journal of Traumatic Stress finds ... who are happily married, communicating frequently with one,s spouse ... the development of posttraumatic stress disorder (PTSD) symptoms after ... male Army soldiers who returned from military deployment within ...
... (BUSM) researchers have found that Gabapentin, (trade name Neurontin) ... and biopolar disease in older and elderly patients, seems ... to experience orgasm, than previously reported. This study ... Journal of Geriatric Pharmacotherapy . Anticonvulsants are the ...
... , THURSDAY, June 2 (HealthDay News) -- People ... hospitalization are more than twice as likely to be readmitted ... a new study has found. The finding suggests that ... patients, according to the researchers, who were to present the ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating ... site infections, new study findings suggest. In the ... Journal of Surgery , the Swiss researchers also said these ... costly hospital stays. "SSIs lead to patients spending up ...
... an investigational vaccine made from their own frozen immune ... with it, according to data being presented by researchers ... 2011 American Society of Clinical Oncology annual meeting in ... In an exploratory, multi-institutional analysis, researchers administered the ...
... By Kathleen Doheny HealthDay Reporter , ... that low-carbohydrate diets, with regular exercise as part of ... some experts have feared. "It,s pretty clear low-carb ... J. Stewart, director of clinical and research exercise physiology ...
Cached Medicine News:Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: